292 related articles for article (PubMed ID: 29558528)
21. The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis.
Gao SH; Huo JB; Pan QM; Li XW; Chen HY; Huang JH
Medicine (Baltimore); 2019 Nov; 98(44):e17541. PubMed ID: 31689755
[TBL] [Abstract][Full Text] [Related]
22. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
23. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms.
Russell J; Raskin J; Wiltse C; Walker D; Brawman-Mintzer O
Psychiatry (Edgmont); 2007 Jun; 4(6):33-45. PubMed ID: 20711334
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of group cognitive-behavioural therapy plus duloxetine for generalised anxiety disorder versus duloxetine alone.
Xie ZJ; Han N; Law S; Li ZW; Chen SY; Xiao JP; Zhang Y; Gao BL; Jiang SS; Gao HM; Huang XB
Acta Neuropsychiatr; 2019 Dec; 31(6):316-324. PubMed ID: 31405402
[TBL] [Abstract][Full Text] [Related]
26. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.
Allgulander C; Nutt D; Detke M; Erickson J; Spann M; Walker D; Ball S; Russell J
J Psychopharmacol; 2008 Jun; 22(4):417-25. PubMed ID: 18635722
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
Allgulander C; Hartford J; Russell J; Ball S; Erickson J; Raskin J; Rynn M
Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
[TBL] [Abstract][Full Text] [Related]
28. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
Ball S; Marangell LB; Lipsius S; Russell JM
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
[TBL] [Abstract][Full Text] [Related]
29. Implications of pain in generalized anxiety disorder: efficacy of duloxetine.
Hartford JT; Endicott J; Kornstein SG; Allgulander C; Wohlreich MM; Russell JM; Perahia DG; Erickson JS
Prim Care Companion J Clin Psychiatry; 2008; 10(3):197-204. PubMed ID: 18615176
[TBL] [Abstract][Full Text] [Related]
30. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
31. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis.
Weng C; Xu J; Wang Q; Lu W; Liu Z
Osteoarthritis Cartilage; 2020 Jun; 28(6):721-734. PubMed ID: 32169731
[TBL] [Abstract][Full Text] [Related]
33. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
Meoni P; Hackett D; Lader M
Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
[TBL] [Abstract][Full Text] [Related]
34. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder.
Steiner M; Allgulander C; Ravindran A; Kosar H; Burt T; Austin C
Hum Psychopharmacol; 2005 Jan; 20(1):3-13. PubMed ID: 15551351
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
36. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
37. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
38. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.
Khan A; Durgam S; Tang X; Ruth A; Mathews M; Gommoll CP
Prim Care Companion CNS Disord; 2016; 18(2):. PubMed ID: 27486544
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis.
Baldwin D; Woods R; Lawson R; Taylor D
BMJ; 2011 Mar; 342():d1199. PubMed ID: 21398351
[TBL] [Abstract][Full Text] [Related]
40. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
